



## ASX RELEASE

### Race Oncology presents at AusBiotech Global Investment Series

**23 March 2017:** Specialty pharmaceutical company, Race Oncology Ltd (ASX: RAC) is pleased to advise that its CEO Peter Molloy, will be presenting at the Hong Kong Biotech Invest 2017 and Australia-China Biotech Invest 2017. The investor events will take place in Hong Kong and Shanghai respectively, between 23 March and 28 March 2017. More information on the events is available through the AusBiotech website (<http://www.ausbiotechinvestment.com.au/>).

The events are designed to connect investors and local companies with Australian life science businesses to discuss investment and partnership opportunities. Mr Molloy will be presenting the latest version of the Race Oncology presentation as recently disclosed to the market on 9 March 2017.

#### About Race Oncology

Race Oncology Limited is a specialty pharmaceutical company, whose business model is to pursue later stage assets, principally in the cancer field. The Company's first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s. Race Oncology owns recent patent filings on Bisantrene and has secured Orphan Drug Designation in the US. The Company's goal is to complete final development of Bisantrene and bring this valuable cancer drug to market. Visit [raceoncology.com](http://raceoncology.com) for more information.

For more information, contact:

**Peter Molloy**                      T: +61 (0) 3 9097 1656  
**Managing Director**            E: [plmolloy@raceoncology.com](mailto:plmolloy@raceoncology.com)

#### Investor Relations

##### FTI Consulting

T: +61 (0)8 9485 8888

E: [Elodie.Castagna@fticonsulting.com](mailto:Elodie.Castagna@fticonsulting.com) / [Steve.Suleski@fticonsulting.com](mailto:Steve.Suleski@fticonsulting.com)